Omeros Corporation (FRA:3O8)
8.24
+0.50 (6.46%)
At close: Dec 19, 2025
Omeros Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
202
Market Cap
580.86M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 29.87M | -34.96M | -53.93% |
| Dec 31, 2017 | 64.83M | 23.21M | 55.77% |
| Dec 31, 2016 | 41.62M | 28.11M | 208.07% |
| Dec 31, 2015 | 13.51M | 12.97M | 2,406.31% |
| Dec 31, 2014 | 539.00K | -1.06M | -66.31% |
| Dec 31, 2013 | 1.60M | -4.42M | -73.43% |
| Dec 31, 2012 | 6.02M | 1.50M | 33.11% |
| Dec 31, 2011 | 4.52M | 2.42M | 114.92% |
| Dec 31, 2010 | 2.11M | 661.00K | 45.78% |
| Dec 31, 2009 | 1.44M | 274.00K | 23.42% |
| Dec 31, 2008 | 1.17M | -753.00K | -39.16% |
| Dec 31, 2007 | 1.92M | 1.52M | 380.75% |
| Dec 31, 2006 | 400.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Deutsche Post AG | 84.05B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
Omeros News
- 20 days ago - Omeros (OMER) Receives Consistent 'Buy' Rating from D. Boral Capital | OMER Stock News - GuruFocus
- 20 days ago - Omeros (OMER) Secures $2.1B Deal with Novo Nordisk - GuruFocus
- 21 days ago - Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart - Seeking Alpha
- 21 days ago - Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Wallstreet:Online
- 21 days ago - Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) - Business Wire
- 4 weeks ago - Omeros: Key Milestone Ahead, Risk-Averse Investors Should Avoid - Seeking Alpha
- 4 weeks ago - Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Omeros (OMER) Q3 2025 Earnings Call Transcript - The Motley Fool